Journal Mobile Options
Table of Contents
Vol. 79, No. 1, 2007
Issue release date: July 2007
Urol Int 2007;79:13–18

Hormonal Predictors of Prostate Cancer

Sofikerim M. · Eskicorapcı S. · Oruç Ö. · Özen H.
Department of Urology, Hacettepe University School of Medicine, Ankara, Turkey

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Introduction: Androgens are necessary for the development and functioning of the prostate gland. The association of serum testosterone and pituitary hormone levels with prostate cancer development is not completely understood. In this clinical study, we evaluated the role of serum testosterone, free testosterone, luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels in predicting prostate cancer risk in patients who had transrectal ultrasonography-guided prostate biopsy with the suspicion of prostate cancer. Material and Methods: A total of 211 patients who were selected to undergo prostatic biopsy due to abnormal digital rectal examination and/or a serum prostate-specific antigen (PSA) level >2.5 ng/ml were included in the study. The patient characteristics of total PSA, free/total PSA ratio, serum total testosterone, free testosterone, free/total testosterone ratio, FSH and LH levels were compared according to the pathological diagnosis. Results: The mean age was 63.91 years (range 44–83) and the mean PSA level was 9.23 ng/ml (range 0.13–50.41) in the whole group. Of 211 patients, 69 (32.7%) were positive for prostate cancer. The patients who were positive for prostate cancer had statistically lower levels of serum total testosterone compared with the patients who were diagnosed as having benign prostatic hyperplasia (BPH; 405 vs. 450.5 ng/dl, respectively; p = 0.013). The serum FSH level was significantly higher in men with prostatic cancer than in men with BPH (7.56 vs. 6.06 mIU/ml, respectively; p = 0.029). No significant differences between men with prostatic cancer and those with BPH were found for serum LH levels. When normal ranges for serum free and total testosterone levels were defined as 9 pg/ml and 300 ng/dl, respectively, patients who had low free testosterone and total testosterone levels had significantly higher cancer detection rates than patients with high serum androgen levels: 40.8% (40/98) versus 25.6% (29/113) (p = 0.021), and 48.6% (18/37) versus 29.3% (51/174), respectively (p = 0.023). After logistic regression analysis, none of the hormones showed a significant difference in predicting the risk of prostate cancer in patients undergoing prostate biopsy with suspicion of the disease. Conclusion: Our data suggest that patients diagnosed with prostate cancer have low levels of serum testosterone and high levels of serum FSH compared with the patients with BPH. No support was found for the theory that high levels of testosterone increase prostate cancer risk. Further studies are needed to clarify the relationship between hormones and prostate cancer etiology.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Ross R, Bernstein L, Judd H, Hanisch R, Pike M, Henderson B: Serum testosterone levels in healthy young black and white men. J Natl Cancer Inst 1986;76:45.
  2. Mohr AB, Feldman AH, Kalish L, Longcope C, McKinlay JB: Are serum hormones associated with the risk of prostate cancer? Prospective results from the Massachusetts Male Aging Study. Urology 2001;57:930–935.
  3. Eskicorapci SY, Baydar DE, Akbal C, Sofikerim M, Gunay M, Ekici S, Ozen H: An extended 10-core transrectal ultrasonography guided prostate biopsy protocol improves the detection of prostate cancer. Eur Urol 2004;45:444–448.
  4. Eskicorapci SY, Guliyev F, Akdogan B, Dogan HS, Ergen A, Ozen H: Individualization of the biopsy protocol according to the prostate gland volume for prostate cancer detection. J Urol 2005;173:1536–1540.
  5. Gleason DF, Veterans Administration Cooperative Urological Research Group: Histologic grading and clinical staging of prostatic carcinoma; in Tannenbaum M (ed): Urologic Pathology: The Prostate. Philadelphia, Lea & Febiger, 1977.
  6. Morgentaler A, Bruning CO, DeWolf WC: Occult prostate cancer in men with low testosterone levels. JAMA 1996;276:1904–1906.
  7. Hoffman M, DeGolf W, Morgenthaler A: Is low serum free testosterone a marker for high grade prostate cancer? J Urol 2000;163:824–827.
  8. Andersson SO, Adami HO, Bergström R, Wide l: Serum pituitary and sex steroid hormone levels in the etiology of prostatic cancer – a population-based case-control study. Br J Cancer 1993;68:97–102.
  9. Nomura A, Heilbrun LK, Stemmermann GN, Judd HL: Prediagnostic hormones and the risk of prostate cancer. Cancer Res 1988;48:3515–3517.
  10. Barrett-Connor E, Garland C, McPhillips JB, Khaw KT, Wingard DL: A prospective, population-based study of androstenedione, estrogens, and prostatic cancer. Cancer Res 1990;50:169–173.
  11. Nomura AM, Stemmermann GN, Chyou PH, Henderson BE, Stanczyk FZ: Serum androgens and prostate cancer. Cancer Epidemiol Biomarkers Prev 1996;5:621–625.
  12. Chen C, Weiss SN, Stancyzk FZ, Lewis SK, DiTommaso D, Etzioni R, Barnett MJ, Goodman GE: Endogeneous sex hormones and prostate cancer risk: a case-control study nested within the caratone and retinol efficacy trial. Cancer Epidemiol Biomarkers Prev 2003;12:1410–1416.
  13. Bolelli G, Muti P, Micheli A, Sciajno R, Franceschetti Berrino F: Validity for epidemiological studies of long-term crycon and protein hormones in serum and plasma. Cancer Epidemiol Biomarkers Prev 1995;4:509–513.
  14. Meikle AW, Smith JA, Stringham JD: Production, clearance, and metabolism of testosterone in men with prostatic cancer. Prostate 1987;10:25–31.
  15. Stattin P, Lumme S, Tenkanen L, Alfthan H, Jellum E, Hallmans G, Thoresen S, Hakulinen T, Luostarinen T, Lehtinen M, Dillner J, Stenman UH, Hakama M: High levels of circulating testosterone are not associated with increased prostate cancer risk: a pooled prospective study. Int J Cancer 2004;108:418–424.
  16. Bosland MC: The role of steroid hormones in prostate carcinogenesis. J Natl Cancer Inst 2000;27:67–73.
  17. Miller LR, Partin AW, Chan DW, Bruzek DJ, Dobs AS, Epstein JI, Walsh PC: Influence of radical prostatectomy on serum hormone levels. J Urol 1998;160:449–453.
  18. Hilz H, Graefen M, Noldus J, Hammerer P, Knabbe C, Huland E, Huland H: Advanced prostate cancer is associated with a decrease in serum luteinizing hormone. Eur Urol 2000;38:243–249.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50